• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance.

作者信息

Miura Shinpei, Shibazaki Masahiko, Kasai Shuya, Yasuhira Shinji, Watanabe Ayano, Inoue Tsuyoshi, Kageshita Yuich, Tsunoda Kanako, Takahashi Kazuhiro, Akasaka Toshihide, Masuda Tomoyuki, Maesawa Chihaya

机构信息

Department of Tumor Biology, Institute of Biomedical Science, Iwate Medical University, Iwate, Japan; Department of Dermatology, Iwate Medical University, Iwate, Japan.

Department of Tumor Biology, Institute of Biomedical Science, Iwate Medical University, Iwate, Japan.

出版信息

J Invest Dermatol. 2014 Feb;134(2):553-556. doi: 10.1038/jid.2013.343. Epub 2013 Aug 12.

DOI:10.1038/jid.2013.343
PMID:23938463
Abstract
摘要

相似文献

1
A somatic mutation of the KEAP1 gene in malignant melanoma is involved in aberrant NRF2 activation and an increase in intrinsic drug resistance.恶性黑色素瘤中KEAP1基因的体细胞突变与异常的NRF2激活及内在耐药性增加有关。
J Invest Dermatol. 2014 Feb;134(2):553-556. doi: 10.1038/jid.2013.343. Epub 2013 Aug 12.
2
Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.Keap1的基因改变赋予胆囊癌组成型Nrf2激活及化疗抗性。
Gastroenterology. 2008 Oct;135(4):1358-1368, 1368.e1-4. doi: 10.1053/j.gastro.2008.06.082. Epub 2008 Jul 3.
3
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.非小细胞肺癌中KEAP1-NRF2相互作用功能失调
PLoS Med. 2006 Oct;3(10):e420. doi: 10.1371/journal.pmed.0030420.
4
Nrf2/Keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma.Nrf2/Keap1信号通路与黑色素瘤中氧化应激损伤产物8-羟基-2'-脱氧鸟苷和硝基酪氨酸的表达
Anticancer Res. 2016 Apr;36(4):1497-506.
5
Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.Nrf2 介导的非小细胞肺癌细胞增殖调控的分子机制。
Oncogene. 2012 Nov 8;31(45):4768-77. doi: 10.1038/onc.2011.628. Epub 2012 Jan 16.
6
Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth.前列腺癌细胞中 Kelch-like ECH 相关蛋白 1 功能的丧失会导致化疗耐药和放疗耐药，并促进肿瘤生长。
Mol Cancer Ther. 2010 Feb;9(2):336-46. doi: 10.1158/1535-7163.MCT-09-0589. Epub 2010 Feb 2.
7
A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity.在乳腺癌中发现的Keap1突变会损害其抑制Nrf2活性的能力。
Biochem Biophys Res Commun. 2007 Nov 3;362(4):816-21. doi: 10.1016/j.bbrc.2007.08.051. Epub 2007 Aug 27.
8
Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.KEAP1缺失导致的NRF2组成性激活以及合成三萜类化合物RTA 405对NRF2的药理激活对癌细胞生长的影响存在差异。
PLoS One. 2015 Aug 24;10(8):e0135257. doi: 10.1371/journal.pone.0135257. eCollection 2015.
9
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.芳香化酶抑制剂介导的INrf2（Keap1）下调导致乳腺癌中Nrf2增加及耐药性。
Mol Cancer Ther. 2015 Jul;14(7):1728-37. doi: 10.1158/1535-7163.MCT-14-0672. Epub 2015 May 14.
10
Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer.KEAP1 突变与上皮性卵巢癌中 Nrf2 通路的激活
Cancer Res. 2011 Aug 1;71(15):5081-9. doi: 10.1158/0008-5472.CAN-10-4668. Epub 2011 Jun 15.

引用本文的文献

1
The Cancer Antioxidant Regulation System in Therapeutic Resistance.治疗抗性中的癌症抗氧化调节系统
Antioxidants (Basel). 2024 Jun 27;13(7):778. doi: 10.3390/antiox13070778.
2
Keap1-Nrf2 pathway: a key mechanism in the occurrence and development of cancer.Keap1-Nrf2信号通路：癌症发生发展的关键机制。
Front Oncol. 2024 Apr 3;14:1381467. doi: 10.3389/fonc.2024.1381467. eCollection 2024.
3
Targeting ferroptosis in melanoma: cancer therapeutics.靶向黑色素瘤中的铁死亡：癌症治疗学。

本文引用的文献

1
Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming.Nrf2 将葡萄糖和谷氨酰胺重定向到代谢重编程中的合成代谢途径中。
Cancer Cell. 2012 Jul 10;22(1):66-79. doi: 10.1016/j.ccr.2012.05.016.
2
Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.与维莫非尼及BRAF通路抑制相关的皮肤毒性作用
Arch Dermatol. 2012 May;148(5):628-33. doi: 10.1001/archdermatol.2012.125.
3
Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution.Keap1-Nrf2 通路在应激反应和癌症演化中的分子机制。
Cell Commun Signal. 2023 Nov 23;21(1):337. doi: 10.1186/s12964-023-01296-w.
4
Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma.Nrf2作为黑色素瘤靶向治疗耐药性的治疗靶点
Antioxidants (Basel). 2023 Jun 20;12(6):1313. doi: 10.3390/antiox12061313.
5
The dual role of Nrf2 in melanoma: a systematic review.Nrf2 在黑色素瘤中的双重作用：系统评价。
BMC Mol Cell Biol. 2023 Feb 6;24(1):5. doi: 10.1186/s12860-023-00466-5.
6
NRF2 and Key Transcriptional Targets in Melanoma Redox Manipulation.黑色素瘤氧化还原调控中的NRF2及关键转录靶点
Cancers (Basel). 2022 Mar 16;14(6):1531. doi: 10.3390/cancers14061531.
7
Ultrasound-Responsive Nrf2-Targeting siRNA-Loaded Nanobubbles for Enhancing the Treatment of Melanoma.用于增强黑色素瘤治疗的超声响应性靶向Nrf2的负载小干扰RNA纳米气泡
Pharmaceutics. 2022 Jan 31;14(2):341. doi: 10.3390/pharmaceutics14020341.
8
Proteome analysis of NRF2 inhibition in melanoma reveals CD44 up-regulation and increased apoptosis resistance upon vemurafenib treatment.NRF2 抑制在黑色素瘤中的蛋白质组学分析显示，vemurafenib 治疗后 CD44 上调和凋亡抵抗增加。
Cancer Med. 2022 Feb;11(4):956-967. doi: 10.1002/cam4.4506. Epub 2021 Dec 23.
9
Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies.黑色素瘤及靶向治疗获得性耐药中的氧化应激相关机制
Antioxidants (Basel). 2021 Dec 3;10(12):1942. doi: 10.3390/antiox10121942.
10
Heme oxygenase promotes B-Raf-dependent melanosphere formation.血红素加氧酶促进 B-Raf 依赖性黑素球形成。
Pigment Cell Melanoma Res. 2020 Nov;33(6):850-868. doi: 10.1111/pcmr.12905. Epub 2020 Jul 9.
Genes Cells. 2011 Feb;16(2):123-40. doi: 10.1111/j.1365-2443.2010.01473.x.
4
Narrative review: BRAF opens the door for therapeutic advances in melanoma.叙述性综述：BRAF 为黑色素瘤的治疗进展打开了大门。
Ann Intern Med. 2010 Nov 2;153(9):587-91. doi: 10.7326/0003-4819-153-9-201011020-00008.
5
Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.替莫唑胺通过激活 AMP 激活的蛋白激酶促进胶质母细胞瘤细胞凋亡，途径为 p53 激活和 mTORC1 抑制。
J Biol Chem. 2010 Dec 24;285(52):40461-71. doi: 10.1074/jbc.M110.164046. Epub 2010 Sep 29.
6
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.RAF 抑制剂 PLX4032 以 V600E BRAF 选择性方式抑制 ERK 信号和肿瘤细胞增殖。
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8. doi: 10.1073/pnas.1008990107. Epub 2010 Jul 28.
7
Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005.肢端雀斑样痣黑色素瘤：1986 - 2005年美国的发病率及生存模式
Arch Dermatol. 2009 Apr;145(4):427-34. doi: 10.1001/archdermatol.2008.609.
8
Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.Keap1的基因改变赋予胆囊癌组成型Nrf2激活及化疗抗性。
Gastroenterology. 2008 Oct;135(4):1358-1368, 1368.e1-4. doi: 10.1053/j.gastro.2008.06.082. Epub 2008 Jul 3.
9
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.发现一种具有强大抗黑色素瘤活性的致癌性B-Raf激酶选择性抑制剂。
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6. doi: 10.1073/pnas.0711741105. Epub 2008 Feb 19.
10
Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.皮肤黑色素瘤亚型显示出不同的BRAF和NRAS突变频率。
Clin Cancer Res. 2006 Aug 1;12(15):4499-505. doi: 10.1158/1078-0432.CCR-05-2447.